Prorenoic acid

Prorenoic acid
Clinical data
Other namesProrenoate; 6α,7α-Dihydro-17-hydroxy-3-oxo-3'H-cyclopropa(6,7)-17α-pregna-4,6-diene-21-carboxylic acid
Drug classAntimineralocorticoid
Identifiers
IUPAC name
  • 3-[(1R,2R,4R,10R,11S,14S,15R,18S)-15-Hydroxy-10,14-dimethyl-7-oxopentacyclo[9.7.0.02,4.05,10.014,18]octadec-5-en-15-yl]propanoate
CAS Number
Chemical and physical data
FormulaC23H31O4
Molar mass371.497 g·mol−1
3D model (JSmol)
SMILES
  • O([H])[C@](CCC(=O)[O-])1CC[C@@]([H])2[C@]1(C)CC[C@@]([H])1[C@](C)3CCC(C=C3[C@@]([H])3C[C@]3([H])[C@@]21[H])=O
InChI
  • InChI=1S/C23H32O4/c1-21-7-3-13(24)11-18(21)14-12-15(14)20-16(21)4-8-22(2)17(20)5-9-23(22,27)10-6-19(25)26/h11,14-17,20,27H,3-10,12H2,1-2H3,(H,25,26)/p-1/t14-,15+,16+,17+,20-,21-,22+,23-/m1/s1
  • Key:OHZWNMVYJJTNKU-VAFIVCJBSA-M

Prorenoic acid, or prorenoate, is a synthetic steroidal antimineralocorticoid which was never marketed.[1][2][3][4]

See also

References

  1. ↑ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1036–. ISBN 978-1-4757-2085-3.
  2. ↑ Claire M, Rafestin-Oblin ME, Michaud A, Roth-Meyer C, Corvol P (1979). "Mechanism of action of a new antialdosterone compound, prorenone". Endocrinology. 104 (4): 1194–200. doi:10.1210/endo-104-4-1194. PMID 436757.
  3. ↑ Netchitailo P, Delarue C, Perroteau I, Jegou S, Tonon MC, Leroux P, Leboulenger F, Kusmierek MC, Capron MH, Vaudry H (1982). "Effect of aldosterone antagonists on mineralocorticoid synthesis in vitro. Inhibition of aldosterone production by prorenoate-K". Eur. J. Pharmacol. 77 (4): 243–9. doi:10.1016/0014-2999(82)90125-x. PMID 6277668.
  4. ↑ I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 234–. ISBN 978-94-011-4439-1.



This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.